WO2009125851A1 - Procédé pour la détection de l’efficacité d’un composé de type dérivé de phénylalanine chez un patient diabétique - Google Patents

Procédé pour la détection de l’efficacité d’un composé de type dérivé de phénylalanine chez un patient diabétique Download PDF

Info

Publication number
WO2009125851A1
WO2009125851A1 PCT/JP2009/057395 JP2009057395W WO2009125851A1 WO 2009125851 A1 WO2009125851 A1 WO 2009125851A1 JP 2009057395 W JP2009057395 W JP 2009057395W WO 2009125851 A1 WO2009125851 A1 WO 2009125851A1
Authority
WO
WIPO (PCT)
Prior art keywords
gene
diabetes
genotype
phenylalanine derivative
group
Prior art date
Application number
PCT/JP2009/057395
Other languages
English (en)
Japanese (ja)
Inventor
義光 山▲崎▼
健 遅野井
Original Assignee
株式会社サインポスト
アステラス製薬株式会社
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 株式会社サインポスト, アステラス製薬株式会社 filed Critical 株式会社サインポスト
Publication of WO2009125851A1 publication Critical patent/WO2009125851A1/fr

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Definitions

  • the present invention relates to a method for detecting the effectiveness of an antidiabetic agent comprising a phenylalanine derivative-based drug as an active ingredient for individual diabetic patients based on genetic information of the diabetic patients.
  • the present invention also relates to a therapeutic agent for diabetes comprising a phenylalanine derivative-based drug used as an active ingredient for a specific diabetic patient having a unique genetic polymorphism.
  • the above-described method of the present invention provides effective and accurate treatment guidelines for treating and improving diabetes to diabetic patients and medical professionals. As a result of selecting therapeutic agents suitable for individual patients, It is useful in that effective and accurate treatment can be performed and the mental, physical and economic burden caused by invalid treatment can be avoided.
  • the number of diabetic patients in Japan is approximately 7.4 million, including the reserve arm that is considered “a person who cannot be denied the possibility of diabetes”. It is estimated that it is about 16.2 million people, one in 6.3 people.
  • the increase in the number of diabetics is said to be greatly affected by changes in dietary habits and aging, and the number of people including the reserves increased by 2.5 million compared to the survey five years ago. Excluding diabetes, it is estimated that the number of people who are strongly suspected will reach 10.8 million.
  • the main pillars of diabetes treatment are diet, exercise, and medication. However, only 50% of people who are strongly suspected of having diabetes are being treated. In addition, there are not a few diabetic patients who once stop treatment after starting treatment, which is thought to lead to an increase in complications. In addition, there are reports that only about 30% of diabetic patients who have already undergone drug treatment have maintained a good state, and a more effective drug selection method is required.
  • HbA 1c hemoglobin A 1c
  • Oral preparations currently used for the treatment of diabetes can be roughly classified into the following three types according to their mechanism of action: (A) insulin secretagogue (sulfonylurea, phenylalanine derivative), (B) a drug (alpha glucosidase inhibitor) that delays the absorption of food and releases the sugar toxicity caused by hyperglycemia, (C) Insulin resistance improving drug (biguanide, thiazolidine drug).
  • EBM Evidence Based Medicine
  • doctors' expertise, experience, and technology evidence based on the latest and best medical technology confirmed by scientific methods
  • the most effective and safe medical care for individual patients is required, and therefore, effective patient groups for the administration of various antidiabetic drugs are based on scientific evidence. It is important to clarify. By doing so, the patient's compliance can be improved, an effective therapeutic effect can be obtained, and the medical expenses can be efficiently operated.
  • Non-patent Document 1 Adiponectin (G276T) (Non-patent document 1), PGC-1 (G1302A) (Non-patent document 2), beta3-Adrenergic Receptor (Trp64Arg) (Non-patent document 3) ), Resistin (C-420G) (Non-patent Document 4), etc. have been identified, and their polymorphisms [for example, SNPs (single nucleotide polymorphisms)] and diabetes have been reported. .
  • Non-Patent Documents 5-6 it has been reported that there are differences between individuals and side effects in the expression of drug effects due to differences in gene polymorphisms that are directly involved in the mechanism of action of specific drugs (for example, Non-Patent Documents 5-6).
  • Non-Patent Documents 5-6 it is not known that genetic polymorphisms of genes other than diabetes-related genes reported in these reports serve as selection indicators for evaluating the effectiveness of various antidiabetic drugs in advance. There is no idea yet to select an effective anti-diabetic drug suitable for the patient based on the genetic information.
  • Hara K.et al Genetic variation in the gene encoding adiponectin is associated with an increased risk of type 2 diabetes in the Japanese population. Diabetes. 2002 Feb; 51 (2): 536-40. Hara K.et al, A genetic variation in the PGC-1 gene could confer insulin resistance and susceptibility to Type II diabetes. Diabetologia. 2002 May; 45 (5): 740-3. Walston J. et al, Time of onset of non-insulin-dependent diabetes mellitus and genetic variation in the beta 3-adrenergic-receptor gene. N Engl J Med. 1995 Aug 10; 333 (6): 343-7. Osawa H.
  • the present invention provides a gene polymorphism related to the effectiveness of an antidiabetic agent comprising a phenylalanine derivative drug as an active ingredient among oral diabetes drugs. Based on this information, the phenylalanine derivative drug is effectively used. The purpose is to select and determine diabetic patients who respond.
  • an object of the present invention is to provide a method for detecting and determining in advance in advance the effectiveness of a therapeutic agent for diabetes comprising the above-described phenylalanine derivative-based drug as an active ingredient for diabetic patients.
  • Another object of the present invention is to provide a therapeutic agent for diabetes suitable for a diabetic patient having a specific gene polymorphism, and to provide a method for treating diabetes suitable for the patient.
  • GYS1 skeletal muscle glycogen synthase gene
  • EPHX2 Soluble epoxide hydrolase
  • BC011628 patients with A (adenine) at position 860 as homozygote (AA) or heterozygote (AG or GA); (3) C at position -159 of the CD14 gene (Genbank Accession No. AF097335) It has been found that patients having cytosine) as a homozygote (CC) or heterozygote (CT or TC) have a markedly improved diabetes-improving effect with a phenylalanine derivative.
  • the GENOTYPE of any of the genes (gene polymorphisms) (1) to (3) above is examined in vitro, and it is confirmed that the GENOTYPE is a specific TYPE. By doing so, it is possible to determine in advance the administration effectiveness of a therapeutic agent for diabetes containing a phenylalanine derivative drug as an active ingredient, and as a result, the therapeutic agent can be selected and determined as an effective therapeutic agent for diabetes for the patient.
  • the present invention has the following aspects.
  • a method for detecting in vitro the effectiveness of administration of a therapeutic agent for diabetes comprising a phenylalanine derivative-based drug as an active ingredient for a diabetic patient, wherein the diabetic patient has at least one of the genes (1) to (3) A method characterized by having the following GENOTYPE (1) as an index:
  • I-2 The method described in I-1, having the following steps: (A) a step of detecting GENOTYPE in a polymorphism of at least one gene described in (1) to (3) above for a biological sample of a diabetic patient; (B) A step of identifying whether the GENOTYPE in the polymorphism of at least one gene described in (1) to (3) is the GENOTYPE (1) described in I-1.
  • I-3 The method according to I-2, further comprising the following step (c): (c) Based on the result of (b) above, GENOTYPE in the polymorphism of at least one gene described in (1) to (3) above is described in (1) to (3) of I-1 above A step of determining that administration of a therapeutic agent for diabetes comprising a phenylalanine derivative-based drug as an active ingredient is effective for the treatment of the diabetic patient when the GENOTYPE (1) matches.
  • the phenylalanine derivative is at least one selected from the group consisting of nateglinide, mitiglinide, repaglinide, and pharmaceutically acceptable salts thereof, I-1 to I- 3.
  • Antidiabetic agent comprising phenylalanine derivative as active ingredient II-1.
  • Diabetes treatment comprising a phenylalanine derivative-based drug as an active ingredient, which is administered to a diabetic patient whose at least one gene of any one of (1) to (3) is confirmed to have the following GENOTYPE Agent:
  • diabetes therapeutic agent according to II-1 wherein the phenylalanine derivative is nateglinide, mitiglinide, repaglinide, or a pharmaceutically acceptable salt thereof.
  • a method for treating diabetes having:
  • the above-mentioned phenylalanine derivative drug is at least one selected from the group consisting of nateglinide, mitiglinide, repaglinide, and pharmaceutically acceptable salts thereof, described in III-1 How to treat diabetes.
  • phenylalanine derivatives for certain diabetics IV-1.
  • IV-2 Described in IV-1, wherein the phenylalanine derivative is at least one selected from the group consisting of nateglinide, mitiglinide, repaglinide, and pharmaceutically acceptable salts thereof. use.
  • phenylalanine derivative is at least one selected from the group consisting of nateglinide, mitiglinide, repaglinide, and pharmaceutically acceptable salts thereof. Phenylalanine derivative drugs to be described.
  • the GENOTYPE of at least one gene polymorphism of any one of (1) GYS1 (A260G), (2) EPHX2 (G860A), and (3) CD14 (T-159C) is examined for a diabetic patient.
  • the effectiveness of the diabetic patient with respect to the phenylalanine derivative can be detected or determined in advance in vitro.
  • administration of diabetes treatments containing phenylalanine derivative drugs as active ingredients enables accurate and effective treatment of diabetes according to individual patients. It becomes. This, on the other hand, reduces the burden of treatment costs (medical costs) caused by the treatment that is accurate and ineffective for the patient, reduces physical and mental distress due to possible side effects, and delays treatment. It is also effective in preventing diabetes progression and complications.
  • gene in this specification has double-stranded DNA including human genomic DNA, single-stranded DNA (sense strand), and a sequence complementary to the sense strand. Both single-stranded DNA (antisense strand) and fragments thereof are included, and “gene” in the present specification distinguishes a regulatory region, a coding region, an exon, and an intron unless otherwise specified. It shall be shown without doing.
  • GYS1 A260G
  • EPHX2 G860A
  • CD14 T-159C gene polymorphism information (base sequence, chromosome position, etc.) and gene polymorphism described in this specification
  • the position information of the mold is based on the following documents.
  • GYS1 (A260G) Shimomura H, et al.
  • M416V muscle glycogen synthase gene
  • EPHX2 (G860A) Ohtoshi K, et al. Association of soluble epoxide hydrolase gene polymorphism with insulin resistance in type 2 diabetic patients. Biochem Biophys Res Commun. 2005 May 27; 331 (1): 347-350.
  • CD14 T-159C Fernandez-Real JM, et al. CD14 monocyte receptor, involved in the inflammatory cascade, and insulin sensitivity. J Clin Endocrinol Metab. 2003 Apr; 88 (4): 1780-1784. Unkelbach K, et al., A new promoter polymorphism in the gene of lipopolysaccharide receptor CD14 is associated with expired myocardial infarction in patients with low atherosclerotic risk profile. Arterioscler Thromb Vasc Biol. 1999 Apr; 19 (4): 932-8.
  • GYS1 (A260G)
  • GYS1 human GYS1 gene (Genbank Accession No. BC002617) has a gene polymorphism in which the 260th base of the nucleotide sequence is A or G.
  • EPHX2 (G860A)
  • EPHX2 (G860A)
  • CD14 T-159C)
  • AF097335 has a gene polymorphism in which the -159th base of the nucleotide sequence is T or C, respectively. .
  • the SNP position relating to each gene is a position indicated by “+1” as the transcription start point of each gene. That is, the 260th base in the base sequence of the GYS1 gene means the 260th base downstream from the transcription start point of the GYS1 gene.
  • the 860th base in the base sequence of the EPHX2 gene refers to the EPHX2 gene transcription start point. It means the 860th base downstream.
  • the ⁇ 159th base in the base sequence of the CD14 gene means the 159th base upstream from the transcription start point of the CD14 gene, that is, the promoter region ⁇ 159th base of the CD14 gene.
  • Gene polymorphism means the diversity of genes in which two or more types of alleles exist at one locus in the same population. Specifically, it indicates a mutation of a gene that exists at a certain frequency or more in a certain population.
  • the gene mutation referred to here is not limited to the region transcribed as RNA, but includes mutations in all DNAs that can be identified on the human genome including regulatory regions such as promoters and enhancers. 99.9% of human genomic DNA is common among individuals, and the remaining 0.1% is responsible for such diversity, and is involved in individual differences in susceptibility to specific diseases, responsiveness to drugs and environmental factors. obtain.
  • a genetic polymorphism does not always make a difference in phenotype.
  • the SNP (single nucleotide polymorphism) targeted by the present invention is also a kind of genetic polymorphism.
  • the “diabetes” targeted in the present invention is mainly type 2 diabetes (insulin-independent diabetes).
  • type 2 diabetes insulin-independent diabetes
  • the blood glucose level is 200 mg / dL or higher
  • the fasting blood glucose level is 126 mg / dL or higher
  • the 75 g oral glucose tolerance test 2 hour value is 200 mg / dL or higher It can be judged as diabetes.
  • HbA 1c hemoglobin A 1c
  • the HbA 1c value is regarded as important, and the main determination is made based on this.
  • the HbA 1c value is an index that reflects the average blood glucose level of the patient over the past 1 to 2 months, and is the most important index of blood glucose control status with little variation in the value of one patient.
  • the present invention relates to the effectiveness of administration of a therapeutic agent for diabetes containing a phenylalanine derivative-based drug as an active ingredient for diabetic patients.
  • This method can be carried out by in vitro detection of GENOTYPE in at least one gene polymorphism of any one of the following (1) to (3) for a biological sample of a diabetic patient.
  • (1) GYS1 gene will be described as an example.
  • the method of the present invention uses the biological sample of a diabetic patient as a material, and position 260 of the GYS1 gene [GYS1 ( A260G)]) to detect GG homozygote, AG or GA heterozygote, or AA homozygote, and based on the description in Table 6 above, In the case of a homozygote or an AG or GA heterozygote, it can be determined in advance that administration of a phenylalanine derivative-based drug is effective for the treatment of the diabetic patient.
  • GYS1 A260G
  • AG or GA heterozygote ie, AA homozygote
  • a phenylalanine derivative is administered to treat the diabetic patient. Is not very effective and can be determined not to be the first choice.
  • the administration effectiveness of phenylalanine derivative drugs can be detected in advance in vitro in diabetic patients. .
  • the method of the present invention uses a biological sample of a diabetic patient as a material, detects the GENOTYPE at position 860 of the EPHX2 gene [EPHX2 (G860A)], and homozygotes for AA A method of identifying heterozygotes for AG, GA, or homozygotes for GG.
  • EPHX2 G860A
  • homozygotes for AA A method of identifying heterozygotes for AG, GA, or homozygotes for GG.
  • AA homozygote or AG or GA heterozygote it can be determined in advance that administration of a phenylalanine derivative is effective for the treatment of the diabetic patient.
  • a GG homozygote it can be determined that administration of a phenylalanine derivative-based drug is not very effective for the treatment of the diabetic patient and is not a first option.
  • the method of the present invention uses a biological sample of a diabetic patient as a material to detect the GENOTYPE at position -159 (CD14 (T-159C)) of the promoter region of the CD14 gene, and A method of identifying another homozygote, CT or TC heterozygote, or TT homozygote.
  • CD14 T-159C
  • TT TT homozygote
  • genes (1) to (3) are gene markers indicating the effectiveness of phenylalanine derivative drugs (sensitivity to phenylalanine derivative drugs) in diabetic patients.
  • the gene marker can be suitably used for diabetic patients to determine whether administration of phenylalanine derivative drugs is effective for the treatment of diabetes. If the target patient gene (gene polymorphism) matches the GENOTYPE (1) shown in Table 6 above, the patient is responsive (sensitive) to the phenylalanine derivative drug, that is, the phenylalanine derivative drug. Means that the patient is effective in treating diabetes.
  • phenylalanine derivative drug targeted here will be described in detail in (3) below.
  • Preferable phenylalanine derivative drugs include nateglinide, mitiglinide, repaglinide and pharmaceutically acceptable salts thereof.
  • these drugs are administered in an effective amount in one or a combination of two or more as necessary to diabetic patients determined to be responsive (sensitive) to phenylalanine derivative drugs by the method of the present invention. can do.
  • genotype detection is performed by (i) performing PCR in a region containing at least one gene polymorphism described in (1) to (3) on the subject's genomic DNA, and using the SSCP method.
  • the subject is genomic DNA of the subject
  • PCR is performed in the region containing the gene polymorphism of at least one gene described in (1) to (3), and the restriction enzyme cleavage pattern for the PCR product
  • Iii a method in which the PCR product is directly sequenced and sequenced
  • ASO allele specific oligonucleotide
  • the method of the present invention can be carried out by performing the following steps (a) and (b): (A) a step of detecting GENOTYPE in a genetic polymorphism of at least one gene described in (1) to (3) for a biological sample of a diabetic patient; (B) A step of identifying whether the GENOTYPE in the polymorphism of at least one gene described in (1) to (3) is GENOTYPE (1) described in Table 6 above.
  • step (a) can be performed specifically on genomic DNA extracted from a biological sample of a diabetic patient.
  • Such a determination step is not an essential step of the method of the present invention, but such a determination step can optionally be included as the following step (c): (c) Based on the result of (b) above, the GENOTYPE in the polymorphism of at least one gene described in (1) to (3) of diabetic patients matches the GENOTYPE (1) described in Table 6 above. If it is determined that the administration of a phenylalanine derivative is effective for the treatment of the diabetic patient, and conversely does not match the GENOTYPE (1) described in Table 6 above, A step of judging that administration of a phenylalanine derivative is not very effective.
  • the method of the present invention it is possible to determine the presence or absence of administration effectiveness of a phenylalanine derivative-based drug for diabetic patients. This decision can be made even by a specialist by determining whether the genetic polymorphisms of the above (1) to (3) genes in diabetes patients fall under the GENOTYPE (1) shown in Table 6 above. Extremely difficult decisions can be made automatically / mechanically.
  • steps (a) and (b) are known methods (for example, Bruce, et al., Geneme Analysis / A laboratory Manual (vol.4), Cold Spring Harbor Laboratory, NY., (1999)). Can be used.
  • genomic DNA can be any cell (including cultured cells, excluding germ cells), tissue (including cultured tissue), or body fluid (eg, blood, saliva, lymph, airway mucosa, semen, isolated from a diabetic patient. , Sweat, urine, etc.) can be prepared as a material. Preferably it is blood or urine.
  • extraction of the genomic DNA is not limited to the above method, methods well known in the art (e.g., Sambrook J. et al,.. "Molecular Cloning:. A Laboratry Manual (2 nd Ed)" Cold Spring Harbor Laboratory, NY) and commercially available DNA extraction kits can be used.
  • step (b) the base located at the gene polymorphic site of at least one gene of (1) to (3) is identified from the extract containing human genomic DNA obtained as described above.
  • the base located at the gene polymorphic site of at least one gene of (1) to (3) is identified from the extract containing human genomic DNA obtained as described above.
  • RFLP Method of determination
  • polymorphic-specific probes for example, a specific probe is stuck on a chip, glass slide, nylon membrane, and hybridization intensity for those probes
  • RFLP Method of determination
  • Fluorescence emitted by a certain type of double-strand-specific fluorescent dyes can be obtained by following the change in temperature.
  • a method in which a base-extension reaction is performed by polymerase from a template-specific primer and a base incorporated into a polymorphic site at that time is identified (by using dideoxynucleotide, each is fluorescently labeled, and each fluorescence is Detection method, method of detecting incorporated dideoxynucleotide by mass spectrometry), and further using template-specific primers followed by the presence or absence of base pairs complementary to the mutation site or non-complementary base pairs. There is a method to make it recognize.
  • gene polymorphism detection methods are typical gene polymorphism detection methods, but the method of the present invention is not limited to these, and other known or future gene polymorphism detection methods can be widely used. Moreover, when detecting the gene polymorphism of the present invention, these gene polymorphism detection methods may be used singly or in combination of two or more.
  • the method of the present invention is not limited to the method of directly detecting and identifying the GENOTYPE of the gene.
  • a method of detecting the amino acid sequence of a protein that is an expression product of a gene and identifying the presence or absence of an amino acid mutation can also be employed.
  • the GYS1 gene has a mutation in the 416th amino acid (Met) of exon 10 based on the above gene polymorphism (Met416Val) (Diabetologia.
  • the EPHX2 gene is known to have a mutation at the 287th amino acid (Arg) based on the above polymorphism (Arg287Gln) (Circulation. 2004 Jan 27; 109 (3): 335-9. Epub 2004 Jan19 .).
  • Probes and primers for example, for detecting and distinguishing gene polymorphisms of the above (1) to (3), for each diabetic patient, select whether or not the patient is a person who is effectively administered a phenylalanine derivative. Can be used as a tool for
  • the steps (b) and (c) of the method of the present invention can also be performed by electronic information processing.
  • a method using the electronic information processing will be described with reference to the flowchart shown in FIG.
  • Each processing described below includes a CPU, a memory, a recording device (for example, a hard disk), an input device (for example, a keyboard, a mouse, a flexible disk drive, a CD-ROM drive), a display device (for example, a liquid crystal display), and a communication device (for example).
  • a computer equipped with a network board is used.
  • the processing target data is input via the input device and the communication device and recorded in the recording device, and the CPU executes processing on the data read from the recording device using the memory as a work area.
  • the intermediate result of the process and the final result are recorded in a predetermined area of the recording unit as necessary.
  • the gene information includes at least one gene polymorphism (GENOTYPE) information selected from GYS1 (A260G), EPHX2 (G860A), and CD14 (T-590C). Specifically, it is a pair of text data representing a gene polymorphism name and text data representing its GENOTYPE.
  • the gene information may be input as a code. For example, a code (text data) assigned to each gene polymorphism name or GENOTYPE may be input.
  • the genetic information may be input via a keyboard, may be input via a read drive from a state recorded on a recording medium, or may be input via a communication line. Furthermore, the genetic information may be input by being selected from a plurality of candidates displayed on the display device, or may be input using other known methods.
  • step S2 the genetic polymorphism information table is read from the recording unit.
  • Table 7 shows an example of a table recorded in advance in the recording device.
  • genes (gene polymorphisms) and GENOTYPE are described.
  • the gene (gene polymorphism) and GENOTYPE correspond to the gene polymorphism information.
  • the data shown in Table 7 and the data indicating the corresponding relationship are recorded as text data, for example, in the recording device.
  • step S3 it is determined whether the genetic polymorphism information in the table read in step S2 is included in the patient genetic information input in step S1, and the result is temporarily stored in a predetermined area of the memory. Record. For example, in Table 7, “GYS1 (A260G)” and “GG or AG” in the first row are read, the gene (gene polymorphism) is “GYS1 (A260G)”, and GENOTYPE is “GG or AG”. It is determined whether the genetic polymorphism information is included in the patient genetic information. If it is included, for example, “1” is set in a flag corresponding to the genetic polymorphism information in the first row (assumed that the initial value is set to “0” on the memory).
  • the process may move to step S4 without processing the remaining genetic polymorphism information.
  • step S4 according to the determination result in step S3, whether or not the therapeutic agent for diabetes containing a phenylalanine derivative-based drug as an active ingredient is effective for the patient is displayed (for example, displayed on a display device). For example, if at least one of the above flag values is “1”, it indicates that it is valid, and if all the flag values are “0”, it indicates that it is not valid.
  • the effectiveness of administering a therapeutic agent for diabetes containing a phenylalanine derivative-based drug as an active ingredient to the patient can be determined in advance according to the genetic information possessed by the specific diabetic patient.
  • the present invention is to select a therapeutic agent for diabetes containing a phenylalanine derivative as an active ingredient as an effective drug for a specific diabetic patient having GENOTYPE (1) from a plurality of therapeutic agents for diabetes. It can also be used effectively.
  • the table used for the determination is not limited to the table shown in Table 7, but may be any table including the gene (gene polymorphism) and GENOTYPE information shown in Table 7.
  • the embodiment of the present invention has been described as processing performed using electronic data corresponding to a table according to the flowchart shown in FIG. 1, but the present invention is not limited to this. It is only necessary to use the table shown in the table or a table containing genetic polymorphism information equivalent to this (both are not limited to electronic data). It is also possible to determine whether the described gene (gene polymorphism) and GENOTYPE are included, and to determine the effectiveness of a therapeutic agent for diabetes containing a phenylalanine derivative as an active ingredient for the patient.
  • Diabetes therapeutic agent comprising phenylalanine derivative-based drug as active ingredient
  • the diabetes therapeutic agent provided by the present invention has at least one gene (gene polymorphism) of any of the following (1) to (3) shown below as GENOTYPE: (1) A drug containing a phenylalanine derivative as an active ingredient, which is effective for diabetic patients. The drug is administered to a diabetic patient in which at least one of the following genes (1) to (3) is confirmed to have the following GENOTYPE (1): .
  • a diabetic patient to be treated by the therapeutic agent for diabetes of the present invention has been confirmed to have the above-mentioned GENOTYPE (1) for at least one gene among the above (1) to (3) by genetic testing
  • the patient may be a patient having the above-described GENOTYPE (1) for any two or more genes.
  • the genetic test means a test for examining a genetic polymorphism of at least one gene described in the above (1) to (3). Specifically, an inspection method having the steps (a) and (b) described in the above (2), and an inspection method further having the step (c) in addition to the steps (a) and (b) are given. be able to.
  • the phenylalanine derivative-based drug which is an active ingredient of the therapeutic agent for diabetes of the present invention suppresses an ATP-dependent K channel composed of a sulfonylurea receptor (SUR1) and an inward rectifier K + channel in pancreatic ⁇ cells. It is a drug that promotes insulin secretion by allowing extracellular calcium to flow into the cell membrane.
  • the therapeutic agent for diabetes of the present invention is not particularly limited as long as it contains, as an active ingredient, a phenylalanine derivative based on such an action mechanism that induces insulin secretion and lowers blood glucose.
  • phenylalanine derivative drugs targeted here include the compounds represented by the following general formula (I) and related compounds:
  • R 1 is a hydrogen atom, an alkyl group having 1 to 5 carbon atoms, an aryl group having 6 to 12 carbon atoms, or an aralkyl group having 6 to 12 carbon atoms;
  • R 2 may have a substituent
  • R 3 is a hydrogen atom or an alkyl group having 1 to 6 carbon atoms
  • A is —N— or —CH Means-).
  • the alkyl group having 1 to 5 carbon atoms represented by R 1 in the formula (I) is a methyl group, an ethyl group, an n-propyl group, an isopropyl group, or an n-butyl group.
  • an aryl group having 6 to 12 carbon atoms is a phenyl group, a tolyl group or a naphthyl group; and an aralkyl group having 6 to 12 carbon atoms is preferably a benzyl group:
  • the aryl group having 6 to 12 carbon atoms represented by R 2 is a phenyl group, a naphthyl group or an indanyl group;
  • the hetero 5-membered ring is a 2-benzofuranyl group;
  • the hetero 6-membered ring Is a quinolinyl group and a pyridyl group;
  • a cycloalkyl group is a cyclohexyl group and a cyclopentyl group; or a cycloalkenyl group is a 1-cyclohexenyl group, a 2-cyclohexenyl group, a 3-cyclohexenyl group, a 1-cyclopen
  • Substituents include halogen atoms (for example, fluorine atoms or chlorine atoms), alkyl groups having 1 to 5 carbon atoms (for example, methyl group, ethyl group, n-propyl group, isopropyl group, n-butyl group, sec-butyl group) ), An alkenyl group having 1 to 5 carbon atoms (for example, ethenyl group, propenyl group, butenyl group), an alkyloxy group having 1 to 5 carbon atoms (for example, methoxy group, ethoxy group), an alkyloxy group having 1 to 5 carbon atoms An alkyl group having 1 to 5 carbon atoms (eg, methoxymethyl group, 1-ethoxyethyl group) substituted with a group, an alkylene group having 1 to 5 carbon atoms substituted with an alkyloxy group having 1 to 5 carbon atoms (eg, , A methoxyethylene group), and an
  • the alkyl group having 1 to 6 carbon atoms represented by R 3 is preferably the same as the alkyl group described for R 1 .
  • A is —N— (nitrogen atom) or —CH— (methylene group in which one hydrogen atom is substituted with R 3 ), and these can be arbitrarily selected.
  • the compound (I) in which A is —N— can also be defined as a D-phenylalanine derivative, and the compound (I) in which A is —CH— can be defined as a benzyl succinic acid derivative.
  • the phenylalanine derivative-based drug referred to in the present invention includes hydrates and pharmaceutically acceptable salts of the compound represented by the above formula (I).
  • the salt herein include alkali metal salts such as sodium and potassium, alkaline earth metal salts such as calcium and magnesium; non-ammonium such as ammonium, tetramethylammonium, tetraethylammonium, methylamine, dimethylamine, trimethylamine, triethylamine, and ethylamine. Toxic ammonium, quaternary ammonium and amine cations can be exemplified.
  • Preferred as a phenylalanine derivative-based drug is a compound corresponding to a D-phenylalanine derivative, and nateglinide represented by the following formula (1) [trade name “Starsys Tablets” (Astellas Pharma, etc.):
  • repaglinide represented by the following formula (3) [“SMP-508” (Dainippon Sumitomo Pharma Co., Ltd.), trade name “NovoNorm”: Novo Nordisk Can be mentioned:
  • the anti-diabetic agent of the present invention only needs to contain these phenylalanine derivative drugs in an effective amount that exerts a therapeutic effect on diabetes, and as long as other components, such as pharmaceutically acceptable carriers and additives, are used. May be contained.
  • the therapeutic agent for diabetes of the present invention can usually be administered orally and is in a form suitable for their administration (for example, tablets, pills, powders, solutions, suspensions, emulsions, granules, capsules, etc.). Can be taken.
  • the pharmaceutically acceptable carrier that can be blended in the antidiabetic agent
  • those commonly used in the art can be widely used depending on the above various administration forms.
  • a filler a bulking agent, a binder, a moistening agent, a disintegrating agent, a surfactant, a lubricant, a buffering agent, a chelating agent, a pH adjusting agent, a surfactant and the like can be mentioned.
  • stabilizers, bactericides, coloring agents, preservatives, fragrances, flavoring agents, sweetening agents, and the like can be blended with the antidiabetic agent of the present invention as necessary.
  • the therapeutic agent for diabetes of the present invention can be prepared in the form of a sustained-release preparation or a sustained-release preparation containing a phenylalanine derivative drug as an active ingredient according to a known method.
  • the amount of the phenylalanine derivative-based drug to be contained in the therapeutic agent for diabetes of the present invention is not particularly limited and is appropriately selected from a wide range, but is usually preferably about 1 to 70% by weight.
  • the dosage and mode of administration of the therapeutic agent for diabetes of the present invention depends on the type of phenylalanine derivative-based drug to be blended as an active ingredient, various pharmaceutical forms, patient age, sex and other conditions, and the degree of disease.
  • Administered by the method For example, nateglinide is administered 90 to 120 mg at a time, 3 times a day immediately before each meal (within 10 minutes before meal); mitiglinide calcium hydrate is administered at a dose of 10 mg, 3 times a day, immediately before each meal (within 10 minutes before a meal). It is recommended to do.
  • the present invention relates to a diabetic treatment method performed for diabetic patients. Specifically, the method is intended for patients with type 2 diabetes who have undergone genetic testing and have been confirmed that at least one of the following genes (1) to (3) has GENOTYPE (1). This can be carried out by administering a drug containing a phenylalanine derivative drug as an active ingredient to a patient.
  • the diabetic patient who is the target of the treatment method of the present invention is a patient who has undergone genetic testing and has been confirmed to have the above-mentioned GENOTYPE (1) for at least one of the genes (1) to (3). What is necessary is just to be a patient who has said GENOTYPE (1) about these arbitrary two or more genes.
  • the genetic test means a test for examining a genetic polymorphism of at least one gene described in the above (1) to (3). Specifically, an inspection method having the steps (a) and (b) described in the above (2), and an inspection method further having the step (c) in addition to the steps (a) and (b) are given. be able to.
  • phenylalanine derivative drugs to be administered to the patient and the administration method thereof are as described in (3) above.
  • phenylalanine is applied to a patient who has been subjected to a genetic test in advance and has been confirmed to have the GENOTYPE (1) for at least one of the genes (1) to (3).
  • the above-described genetic test is performed on patients with type 2 diabetes prior to the administration of the phenylalanine derivative drug, and the above (1) to (3)
  • a method including a step of detecting and selecting a patient having the above-described GENOTYPE (1) for at least one gene may be used.
  • GENOTYPE and hemoglobin A1c were measured. Based on the results, each patient was classified into GENOTYPE (1) and (2) for each gene shown in Table 10, and further classified into a group with HbA1c of 6.5% or more and a group with less than 6.5%. By the way, if HbA1c is reduced to less than 6.5%, it is recognized that the administration of phenylalanine derivatives is effective in the treatment of diabetes.
  • GYS (A260G) Patients with type 2 diabetes whose GENOTYPE is GENOTYPE (1) (ie, GG or AG or GA), the percentage of patients whose HbA 1c value was reduced to less than 6.5% by administering phenylalanine derivatives Is significantly more than type 2 diabetic patients with GENOTYPE (2) (ie AA). That is, the phenylalanine derivative drug is more effective for the treatment of diabetes in patients with type 2 diabetes whose GYS (A260G) is GENOTYPE (2).
  • EPHX2 (G860A) Patients with type 2 diabetes whose GENOTYPE is GENOTYPE (1) (ie, AA, AG, or GA), the percentage of patients whose HbA 1c value was reduced to less than 6.5% by administering phenylalanine derivatives was GENOTYPE Is significantly higher than type 2 diabetic patients with GENOTYPE (2) (ie GG). That is, the phenylalanine derivative-based drug is more effective in treating diabetes in patients with type 2 diabetes whose EPHX2 (G860A) is GENOTYPE (2).
  • CD14 Patients with type 2 diabetes whose GENOTYPE is GENOTYPE (1) (ie, CC, CT, or TC), the percentage of patients whose HbA 1c value was reduced to less than 6.5% by administering phenylalanine derivatives Is significantly higher than type 2 diabetic patients with GENOTYPE (2) (ie TT). That is, the phenylalanine derivative drug is more effective for the treatment of diabetes in patients with type 2 diabetes whose CD14 (T-159C) is GENOTYPE (2).

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Physics & Mathematics (AREA)
  • Obesity (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)

Abstract

La présente invention concerne un procédé pour sélectionner et identifier un patient diabétique pour lequel un composé de type dérivé de phénylalanine (par exemple, le natéglinide) est efficace sur la base du polymorphisme génique associé à l’efficacité d’un agent thérapeutique pour le diabète comprenant le composé en tant que principe actif. La présente invention concerne en outre une substance qui est efficace pour le traitement du diabète. Le procédé est réalisé en utilisant, en tant qu’indicateur, le fait qu’un patient diabétique d’intérêt a un génotype représenté dans « GÉNOTYPES (1) » en ce qui concerne au moins un gène choisi parmi les gènes (1) à (3).
PCT/JP2009/057395 2008-04-11 2009-04-10 Procédé pour la détection de l’efficacité d’un composé de type dérivé de phénylalanine chez un patient diabétique WO2009125851A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2008103692A JP2011125218A (ja) 2008-04-11 2008-04-11 糖尿病患者のフェニルアラニン誘導体系薬物感受性予測方法
JP2008-103692 2008-04-11

Publications (1)

Publication Number Publication Date
WO2009125851A1 true WO2009125851A1 (fr) 2009-10-15

Family

ID=41161982

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2009/057395 WO2009125851A1 (fr) 2008-04-11 2009-04-10 Procédé pour la détection de l’efficacité d’un composé de type dérivé de phénylalanine chez un patient diabétique

Country Status (2)

Country Link
JP (1) JP2011125218A (fr)
WO (1) WO2009125851A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6296752B2 (ja) * 2013-10-24 2018-03-20 株式会社サインポスト 糖尿病治療薬の投与量を判定する方法、判定装置、プログラムおよび記録媒体
JP6253560B2 (ja) * 2014-10-01 2017-12-27 株式会社サインポスト 糖尿病治療薬の有効性を判定する装置、プログラムおよび記録媒体

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001032928A2 (fr) * 1999-11-05 2001-05-10 Phase-1 Molecular Toxicology Methodes permettant de determiner une hypersensibilite a un agent
JP2005526788A (ja) * 2002-03-22 2005-09-08 ノバルティス アクチエンゲゼルシャフト 有機化合物の組合せ
WO2006126618A1 (fr) * 2005-05-26 2006-11-30 Signpost Corporation Procédé de détermination de polymorphisme de gène pour évaluer le niveau de risque de maladie, procédé d’évaluation du niveau de risque de maladie et matrice d'évaluation correspondante
JP2008148666A (ja) * 2006-12-20 2008-07-03 Japan Health Science Foundation Ｃｙｐ２ｃ８の薬物代謝能の検査方法、該方法に用いられるプローブおよび検査キット。

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001032928A2 (fr) * 1999-11-05 2001-05-10 Phase-1 Molecular Toxicology Methodes permettant de determiner une hypersensibilite a un agent
JP2005526788A (ja) * 2002-03-22 2005-09-08 ノバルティス アクチエンゲゼルシャフト 有機化合物の組合せ
WO2006126618A1 (fr) * 2005-05-26 2006-11-30 Signpost Corporation Procédé de détermination de polymorphisme de gène pour évaluer le niveau de risque de maladie, procédé d’évaluation du niveau de risque de maladie et matrice d'évaluation correspondante
JP2008148666A (ja) * 2006-12-20 2008-07-03 Japan Health Science Foundation Ｃｙｐ２ｃ８の薬物代謝能の検査方法、該方法に用いられるプローブおよび検査キット。

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
KENTARO YAMADA: "Tailor Made Chiryo no Tenbo", JAPANESE JOURNAL OF CLINICAL MEDICINE, vol. 66, no. 7, 28 September 2008 (2008-09-28), pages 493 - 496 *
MANUEL, J. ET AL.: "CD14 monocyte receptor, involved in the inflammatory cascade, and insulin sensitivity", J. CLIN. ENDOCRINOL. METAB., vol. 88, no. 4, 2003, pages 1780 - 1784 *
MASAHIRO HIRATSUKA ET AL.: "Yakuzai Hannosei ni Eikyo o Oyobosu Idenshi Tagata no Kan'i Jinsoku Kenshutsuho no Kaihatsu to sono Rinsho Oyo", YAKUGAKU ZASSHI, vol. 122, no. 7, 2002, pages 451 - 463 *
OHTOSHI, K. ET AL.: "Association of soluble epoxide hydrolase gene polymorphism with insulin resistance in type 2 diabetic patients", BIOCHM. BIOPHYS. RES. COMM., vol. 331, 2005, pages 347 - 350 *
RISSANEN, J. ET AL.: "New variants in the glycogen synthase gene (Gln71His, Met416Val) in patients with NIDDM from eastern Finland", DIABETOLOGIA, vol. 40, 1997, pages 1313 - 1319 *
SHIMOMURA, H. ET AL.: "A missense mutation of the muscle glycogen synthase gene (M416V) is associated with insulin resistace in the Japanese population", DIABETOLOGIA, vol. 40, 1997, pages 947 - 952 *
TAKEHITO YAMAMOTO ET AL.: "Tonyo Byoyaku ni Kakawaru Taisha Koso to Iden Soin", DIABETES FRONTIER, vol. 16, no. 3, 2005, pages 314 - 318 *

Also Published As

Publication number Publication date
JP2011125218A (ja) 2011-06-30

Similar Documents

Publication Publication Date Title
Eley et al. Association analysis of MAOA and COMT with neuroticism assessed by peers
KR102035877B1 (ko) 우울증이 있는 대상체를 위한 치료 양생법 선택을 위한 검정법 및 치료 방법
US8187811B2 (en) Polymorphisms associated with Parkinson's disease
KR101668122B1 (ko) 체중 관리를 위한 유전자 마커 및 이의 사용 방법
Dracheva et al. Increased serotonin 2C receptor mRNA editing: a possible risk factor for suicide
JP2018023391A (ja) 肝線維症に関連する遺伝的多型、その検出方法および使用
US20140272951A1 (en) Methods of identifying mutations in nucleic acid
Aydin et al. Single nucleotide polymorphism map of five long-QT genes
US20070254289A1 (en) Genetic polymorphisms associated with Alzheimer's Disease, methods of detection and uses thereof
US20150278438A1 (en) Genetic predictors of response to treatment with crhr1 antagonists
Arun Kumar et al. Endothelial nitric oxide synthase gene polymorphisms and the risk of acute myocardial infarction in a South Indian population
EP3011048B1 (fr) Procédé de prédiction de la réponse à un traitement par un antagoniste de v1b chez un patient atteint de symptômes de la dépression et/ou de l'anxiété
JP2013078314A (ja) 冠動脈心疾患に関連する遺伝的多型、その検出方法および使用
Polgár et al. Triglyceride level modifying functional variants of GALTN2 and MLXIPL in patients with ischaemic stroke
US20040203034A1 (en) Optimization of cancer treatment with irinotecan
Prudente et al. The SH2B1 obesity locus is associated with myocardial infarction in diabetic patients and with NO synthase activity in endothelial cells
Tabassum et al. Genetic variants of FOXA2: risk of type 2 diabetes and effect on metabolic traits in North Indians
JP2009518035A (ja) 疼痛感受性および慢性化に関する診断法およびテトラヒドロビオプテリン関連障害に関する診断法
WO2009125851A1 (fr) Procédé pour la détection de l’efficacité d’un composé de type dérivé de phénylalanine chez un patient diabétique
US20110294680A1 (en) Methods and compositions for predicting success in addictive substance cessation and for predicting a risk of addiction
Chiu et al. Hepatic glucokinase promoter polymorphism is associated with hepatic insulin resistance in Asian Indians.
US8236497B2 (en) Methods of diagnosing cardiovascular disease
WO2004029290A2 (fr) Haplotype de susceptibilite a la maladie de parkinson utilise comme un outil pour le criblage genetique
US20020143162A1 (en) Methods
JP2009186425A (ja) ピオグリタゾンまたはその塩による動脈硬化の進展抑制または心血管イベントの発症抑制

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09731446

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09731446

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: JP